Dr. Michael Pawlak - NMI.de

Arbeitsgebiete

- Entwicklung und Anwendung von Protein Mikroarrays und miniaturisierten multiplexen Immunoassays für die Proteomforschung

- Forschungs-, Entwicklungs- und Dienstleitungsprojekte mit Partnern der Pharmaindustrie und der klinischen Forschung

- Reverse-phase Protein Arrrays (RPA) für die Analyse der Proteinsignaltransduktion in behandelten Zellsystemen und Geweben (Tumoren)

- Untersuchungen zur Aufklärung von Krankheitsmechanismen

- Wirk-mechanismen von Medikamentenkandidaten

- Suche nach frühen diagnostischen, pharmacodynamischen und prediktiven Biomarkern für Anwendung in der Indvidualmedizin

Werdegang mit den wichtigsten Stationen

Seit 04/2005 Gruppenleiter Protein Profiling am NMI

1999 - 2005 Mitgründer der Firma Zeptosens in Witterswil, Schweiz (SpinOff Novartis, heute Bayer Technology Services) und Direktor Protein Mikroarrays; verantwortlich für die Ent-wicklung und Kommerzialisierung von Mikroarray Lösungen für die Proteomik; (Mit-) Erfinder zahlreicher Patente

1994 - 1999 Novartis Pharma AG, Basel, Schweiz
Laborleiter In Vitro Metabolismus, ADME, präklinische Medikamentenentwicklung
Laborleiter Bioanalytische Forschung (ehemals Ciba-Geigy AG), maßgeblich beteiligt an der Entwicklung der optischen Planaren Wellenleiter Technologie, Basis-Patente.

1991 - 1994 Postdoktorand am Institut für Physikalische Chemie der Polymere und Membranen, Arbeitsgruppe für Biomembranen (Prof. Horst Vogel), Eidgenössische Technische Hochschule Lausanne (EPFL), Schweiz; Entwicklung von elektrischen und optischen Biosensoren, Membranrezeptor Assays

1988 - 1991 Doktorarbeit am Biozentrum der Universität Basel, Institut für Biophysikalische Chemie; elektrische Einzelkanalmessungen, Peptid-basierte porenbildende Toxine

1982 – 1988 Universität Würzburg; Studium der Physik, Nebenfach Biotechnik

Dr. Michael Pawlak

E michael.pawlak@nmi.de

Projekte

Spher4Sys

Publikationen

A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer

Anderle, N., Koch, A., Gierke, B., Keller, A. L., Staebler, A., Hartkopf, A., Brucker, S. Y., Pawlak, M., Schenke-Layland, K., & Schmees, C.

Cancers, 14(12), 2895. https://doi.org/10.3390/cancers14122895
Advancement of precision oncology by integration of highly sensitive protein profiling technologies and patient-derived cell models for functional efficacy testing

Pawlak, M., Templin, M., & Schmees, C.

Immuno-Oncology Insights, 2(4), 171–185. https://doi.org/10.18609/ioi.2021.013
HepaChip-MP – a twenty-four chamber microplate for a continuously perfused liver coculture model

Busche M, Tomilova O, Schütte J, Werner S, Beer M, Groll N, Hagmeyer B, Pawlak M, Jones P D, Schmees C, Becker H, Schnabel J, Gall K, Hemmler R, Matz-Soja M, Damm G, Beuck S, Klaassen T, Moer J, Ullrich A, Runge D, Schenke-Layland K, Gebhardt R und Stelzle M

Lab on a Chip, DOI: 10.1039/d0lc00357c
PGRMC1 effects on metabolism, genomic mutation and CpG methylation imply crucial roles in animal biology and disease

Thejer, B. M., Adhikary, P. P., Teakel, S. L., Fang, J., Weston, P. A., Gurusinghe, S., Anwer, A. G., Gosnell, M., Jazayeri, J. A., Ludescher, M., Gray, L. A., Pawlak, M., Wallace, R. H., Pant, S. D., Wong, M., Fischer, T., New, E. J., Fehm, T. N., Neubauer, H., Goldys, E. M., … Cahill, M. A.

BMC molecular and cell biology, 21(1), 26. https://doi.org/10.1186/s12860-020-00268-z
PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth

Thejer, B. M., Adhikary, P. P., Kaur, A., Teakel, S. L., Van Oosterum, A., Seth, I., Pajic, M., Hannan, K. M., Pavy, M., Poh, P., Jazayeri, J. A., Zaw, T., Pascovici, D., Ludescher, M., Pawlak, M., Cassano, J. C., Turnbull, L., Jazayeri, M., James, A. C., Coorey, C. P., … Cahill, M. A.

BMC molecular and cell biology, 21(1), 24. https://doi.org/10.1186/s12860-020-00256-3
High Precision RPPA: Concept, Features, and Application Performance of the Integrated Zeptosens Platform

Kresbach, G. M., & Pawlak, M.

Advances in experimental medicine and biology, 1188, 31–59. https://doi.org/10.1007/978-981-32-9755-5_3
PGRMC1 Predicts Poor Prognosis and Promotes Tumour Progression of Breast Cancer through Upregulation of ERα Expression

Willibald M, Stahlhut V, Stamm N, Gierke B, Pawlak M, Fehm T, Neubauer H

Senologie. 2018; 15(02):e52. DOI: 10.1055/s-0038-1651821
Functional protein and pathway profiling of patient-derived tumor models for drug testing and precision medicine applications using Reverse Phase Protein Arrays (RPPA)

Gierke B, Bodenhofer M, Schmees C, Pawlak M

European Journal of Cancer. 2018 November 13-16; 103S1 (e21–e1489):e109
Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cell

Willibald M, Bayer G, Stahlhut V, Poschmann G, Stuhler K, Gierke B, Pawlak M, Seeger H, Mueck AO, Niederacher D, Fehm T, Neubauer H

Oncotarget. 2017 Aug 2;8(42):72480-72493. doi: 10.18632/oncotarget.19819. eCollection 2017 Sep 22.
Impact of serum and dialysates obtained from chronic hemodialysis patients maintained on high cut-off membranes on inflammation profile in human THP-1 monocytes

Trojanowicz B, Ulrich C, Fiedler R, Storr M, Boehler T, Martus P, Pawlak M, Glomb MA, Henning C, Templin M, Werner K, Zickler D, Willy K, Schindler R, Girndt M

Hemodial Int. 2017 Jul;21(3):348-358. doi: 10.1111/hdi.12494. Epub 2016 Sep 26.
Reverse Phase Protein Arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models

Pawlak M, Carragher NO (2017)

Drug Discov Today Technol. 2017 Mar;23:7-16. doi: 10.1016/j.ddtec.2017.05.002. Epub 2017 May 30.
Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial

Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, Hulko M, Boehler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Fiedler R, Girndt M

PLoS One. 2017 Jan 13;12(1):e0169024. doi: 10.1371/journal.pone.0169024. eCollection 2017.
High cut-off dialysis in chronic haemodialysis patients

Girndt M, Fiedler R, Martus P, Pawlak M, Storr M, Bohler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Zickler D, Schindler R

Eur J Clin Invest. 2015 Dec;45(12):1333-40. doi: 10.1111/eci.12559.
Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches

Tegnebratt T, Ruge E, Bader S, Ishii N, Aida S, Yoshimura Y, Ooi CH, Lu L, Mitsios N, Meresse V, Mulder J, Pawlak M, Venturi, M, Tessier J, Stone-Elander S

EJNMMI Res. 2014 Dec;4(1):34. doi: 10.1186/s13550-014-0034-6. Epub 2014 Sep 9.
RPPApipe: a pipeline for the analysis of reverse-phase protein array data

Eichner J, Heubach Y, Ruff M, Kohlhof H, Strobl S, Mayer B, Pawlak M, Templin MF

Biosystems. 2014 Aug;122:19-24. doi: 10.1016/j.biosystems.2014.06.009. Epub 2014 Jun 18.
Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society

Akbani R, Becker KF, Carragher N, Goldstein T, de Koning L, Korf U, Liotta L, Mills GB, Nishizuka SS, Pawlak M, Petricoin EF 3rd, Pollard HB, Serrels B, Zhu J

Mol Cell Proteomics. 2014 Jul;13(7):1625-43. doi: 10.1074/mcp.O113.034918. Epub 2014 Apr 28.
Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA)

Bader S, Zajac M, Friess T, Ruge E, Rieder N, Gierke B, Heubach Y, Thomas M, Pawlak M

Mol Cell Proteomics. 2015 Oct;14(10):2775-85. doi: 10.1074/mcp.O114.045542. Epub 2015 Jun 23.
PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways

Kaistha BP, Lorenz H, Schmidt H, Sipos B, Pawlak M, Gierke B, Kreider R, Lankat-Buttgereit B, Sauer M, Fiedler L, Krattenmacher A, Geisel B, Kraus JM, Frese KK, Kelkenberg S, Giese NA, Kestler HA, Gress TM, Buchholz M

Cancer Res. 2016 Jan 1;76(1):96-107. doi: 10.1158/0008-5472.CAN-15-0216. Epub 2015 Dec 15.
EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer

Schneck, H., Gierke, B., Uppenkamp, F., Behrens, B., Niederacher, D., Stoecklein, N. H., Templin, M. F., Pawlak, M., Fehm, T., Neubauer, H.

Proteomics, 9(13), 3535–3548. https://doi.org/10.1002/pmic.200800159
Evaluation of protein profiles from treated xenograft tumor models identifies an antibody panel for FFPE tissue analysis by reverse phase protein arrays

Bader S, Zajac M, Friess T, Ruge E, Rieder N, Gierke B, Heubach Y, Thomas M, Pawlak M

Mol Cell Proteomics. 2015 Oct;14(10):2775-85. doi: 10.1074/mcp.O114.045542. Epub 2015 Jun 23.
Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Tegnebratt T, Ruge E, Bader S, Ishii N, Aida S, Yoshimura Y, Ooi C-H, Lu L, Mitsios N, Meresse V, Mulder J, Pawlak M, Venturi M, Tessier J, Stone-Elander S

EJNMMI Res. 2014 Dec;4(1):34. doi: 10.1186/s13550-014-0034-6. Epub 2014 Sep 9.
Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report: The RPPA (Reverse Phase Protein Array) Society

Akbani R, Becker KF, Carragher N, Goldstein T, de Koning L, Korf U, Liotta L, Mills GB, Nishizuka SS, Pawlak M, Petricoin EF, Pollard HB, Serrels B, Zhu J

Mol Cell Proteomics. 2014 Jul;13(7):1625-43. doi: 10.1074/mcp.O113.034918. Epub 2014 Apr 28.
Multiple Protein Analysis of Formalin-fixed and Paraffin-embedded Tissue Samples with Reverse phase Protein Arrays

Assadi M, Lamerz J, Jarutat T, Farfsing A, Paul H, Gierke B, Breitinger E, Templin MF, Essioux L, Arbogast S, Venturi M, Pawlak M, Langen H, Schindler T

Mol Cell Proteomics. 2013 Sep;12(9):2615-22. doi: 10.1074/mcp.M112.023051. Epub 2013 May 7.
Multiple protein analysis of FFPE tissue samples with reverse-phase protein arrays

Assadi M, Lamerz J, Jarutat T, Farfsing A, Paul H, Gierke B, Breitinger E, Templin MF, Essioux L, Arbogast S, Venturi M, Pawlak M, Langen H, Schindler T

Mol Cell Proteomics. 2013 Sep;12(9):2615-22. doi: 10.1074/mcp.M112.023051. Epub 2013 May 7.
Novel functional profiling approach combining reverse phase protein microarrays and human 3-D ex vivo tissue cultures: expression of apoptosis-related proteins in human colon cancer.

Pirnia F, Pawlak M, Thallinger GG, Gierke B, Templin MF, Kappeler A, Betticher DC, Gloor B, Borner MM

Proteomics. 2009 Jul;9(13):3535-48. doi: 10.1002/pmic.200800159.
Expression of serine/threonine protein-kinases and related factors in normal monkey and human retinas: the mechanistic understanding of a CDK2 inhibitor induced retinal toxicity

Saturno G, Pesenti M, Cavazzoli C, Rossi A, Giusti A, Gierke B, Pawlak M, Venturi M

Toxicol Pathol. 2007 Dec;35(7):972-83. DOI: 10.1080/01926230701748271
Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts

Weissenstein U, Schneider MJ, Pawlak M, Cicenas J, Eppenberger-Castori S, Oroszlan P, Ehret S, Geurts-Moespot A, Sweep FC, Eppenberger U

Proteomics. 2006; 6 (5): 1427-1436. DOI: 10.1002/pmic.200500078
Protein Microarrays - Neue Systeme für die Proteomforschung

Joos TO, Pawlak M, Templin M, Stoll D

GIT Labor-Fachzeitschrift. 2006; 10, page 890-892.

Zurück